Pantopra-Q (Pantoprazole)

Pantoprazole, the active ingredient in Pantopra-Q, is a proton pump inhibitor presented as a 40 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Pantopra-Q as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole acts on the gastric proton pump to manage conditions driven by excess stomach acid.

- Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining. - Erosive oesophagitis: accelerates mucosal healing and reduces further erosion. - Peptic ulcer disease: supports ulcer healing and helps prevent recurrence. - Zollinger‑Ellison syndrome: controls gastric acid hypersecretion associated with the condition.

Adverse reactions to pantoprazole are generally mild to moderate, but clinicians should remain vigilant for less common serious events.

Common Side Effects: - Headache: mild, transient headache reported by some patients. - Diarrhoea: loose stools occurring during early treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach region. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: severe diarrhoea with abdominal cramping. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Bone fractures: increased risk with long‑term use. - Liver enzyme elevation: signs of hepatic stress. - Acute interstitial nephritis: kidney inflammation presenting with fever and rash.

When prescribing pantoprazole, consider patient‑specific factors and monitor for potential complications.

- Assess renal function: dose adjustment may be needed in severe impairment. - Review concomitant medications: potential for drug‑drug interactions. - Use the lowest effective duration: long‑term therapy may increase fracture risk. - Monitor electrolytes: especially magnesium during prolonged use. - Evaluate for H. pylori infection: may require additional eradication therapy. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Pantoprazole can affect the absorption and metabolism of several co‑administered drugs.

Major Interactions (Avoid): - Ketoconazole or itraconazole: reduced antifungal absorption due to higher gastric pH. - Atazanavir: markedly decreased antiviral exposure. - Clopidogrel: diminished antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer coagulation monitoring. - Digoxin: slight rise in serum levels. - Methotrexate (high dose): reduced renal clearance, monitor for toxicity. - HIV protease inhibitors (e.g., darunavir): altered plasma concentrations. - Iron supplements: decreased absorption, consider spacing doses.